ChemPartner
22.12.2023 22:02:41 CET | ACCESS Newswire | Press release
Newly-launched database offers easier access to diverse tumor models and unveils the path to pharmaceutical breakthroughs
SHANGHAI, CHINA / ACCESSWIRE / December 22, 2023 / ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database. This innovative platform serves as a centralized hub, empowering ChemPartner's clientele with seamless access to a wealth of information on the organization's cutting-edge preclinical platforms. The database includes 800+ tumor models, 30+ cancer types, 20,000 genes, 2,300+ pathways, 1,800 SoC data from literature (500 internal), and 30+ analytic modules.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Screenshot of the online Biology Database from ChemPartner
ChemPartner's renowned biology and pharmacology department, known for its vanguard oncology, immunology, CNS, and metabolic services, has curated an extensive collection of in vitro and in vivo models. The database boasts over 2,000 biochemistry assays, 800 cell lines, 500 patient-derived xenograft (PDX) models, 350 cell-derived xenograft (CDX) models, and 50 syngeneic models. Each model is meticulously characterized with comprehensive data encompassing genomics, pharmacology, histopathology, and relevant clinical information.
Cell Line Models - ChemPartner Biology Database
To ensure a smooth and efficient rollout of this substantial volume of data, the database will be introduced in stages. We are delighted to announce that the first stage, featuring cell line data, is now live on https://database.chempartner.com. Subsequent stages will include CDX, syngeneic, and PDX models, followed by biochemistry data.
The Biology Database, a flagship online collaborative platform, prominently features the Tumor Model Database. This revolutionary resource offers an array of features, including:
- Unified Data Hub: Integration of dispersed tumor model data into a centralized database for efficient management and retrieval, simplifying user access to diverse tumor models.
- Detailed Annotations: Each model is accompanied by intricate annotations including genomics, pathology, and pharmacology data, enabling rapid understanding of model characteristics and suitability for specific research needs.
- Rapid Search and Filtering: Multidimensional search and filtering capabilities empower researchers to swiftly locate models based on cancer type, genomic features, drug sensitivity, and more.
- Data Analysis and Mining: Robust tools facilitate tasks like drug mechanism analysis and biomarker discovery through differential gene expression and drug sensitivity analyses, supporting informed research decisions.
- Data Visualization: Intuitive charts, statistics, and visualization tools present complex data clearly and concisely, aiding in model selection and analysis.
Dr. Lilly Xu, President of Shanghai ChemPartner, expressed enthusiasm about the launch saying, "We are excited to provide our customers with access to this powerful new resource. This comprehensive database will make it easier for our customers to find and use the right models for their research, propelling drug development towards new heights with better precision, efficacy, and efficiency."
-
About ChemPartner
ChemPartner is a leading global CRO and CDMO providing drug discovery, development, and manufacturing services to the pharmaceutical and biotechnology industries. With a team of over 2,000 scientists across multiple countries, ChemPartner offers a comprehensive range of services including preclinical pharmacology, toxicology, drug metabolism and pharmacokinetics, chemistry development, and biologics development. For more information, please visit https://chempartner.com and connect with ChemPartner on LinkedIn, X, and YouTube.
Contact Information
Sarah Stapleton
Marketing Director
news@chempartner.com
6504199974
Related Images
|
SOURCE: ChemPartner
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Highlights Data Futures Platform Patent Amid Tokenized Stock Exemption15.10.2026 19:25:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / October 15, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its Method and System for Data Futures Platform patent application (U.S. Patent Application No. 17/441,847), and highlighted the relevance of the disclosed technology to a significant development in the regulatory landscape for tokenized securities. On September 17, 2026, the U.S. Securities and Exchange Commission announced a temporary, conditional "Innovation Exemption" intended to facilitate on-chain trading of certain tokenized National Market System stocks through qualifying Tokenized Securities Venues. The action represents a meaningful regulatory development for market participants exploring blockchain-based securities infrastructure, subject
Valsoft's TAG Software Group Acquires Positive Solutions, a UK Provider of Healthcare and Pharmacy Software15.10.2026 17:00:00 CEST | Press release
MONTRÉAL, QC / ACCESS Newswire / October 15, 2026 / Valsoft Corporation Inc. ("Valsoft"), a Canadian company specializing in the acquisition and long-term development of vertical market software businesses, today announced the acquisition of Positive Solutions Limited ("Positive Solutions"), a UK-based provider of pharmacy management and point-of-sale software for community pharmacies. The acquisition was completed through TAG Software Group, a wholly owned subsidiary of Valsoft. Founded in 1993 and headquartered in Adlington, UK, Positive Solutions provides integrated software that community pharmacies use to dispense medicine and run their retail operations. Its core products, Analyst PMR (patient medication record) and Analyst EPoS (electronic point of sale), support pharmacies ranging from single-site locations to large corporations. The company serves more than 2,500 sites across England, Scotland, and Wales. With this acquisition, TAG Software Group strengthens Valsoft's presence
OMP and Eastman Show Decision Velocity in Practice at Gartner Supply Chain Planning Summit 202615.10.2026 15:00:00 CEST | Press release
ATLANTA, GA / ACCESS Newswire / October 15, 2026 / OMP, a leader in AI-powered supply chain planning, is bringing Eastman to the Gartner Supply Chain Planning Summit 2026 in Denver, CO (November 2-3) to showcase decision velocity in practice. The global specialty materials company will show how it connected its long-term, mid-term, and short-term planning horizons into one cycle. Eastman on connecting its planning horizons In a session at the summit, Sachin Kothari, Manager IBP Excellence at Eastman, and Abhi Patel, Chief Business Operations Officer at OMP, will explain how Eastman moved from three planning horizons that each ran on their own schedule to one connected cycle linking long-, mid-, and short-term planning on a shared view of the value chain. The session also covers what got in the way of the shift and closes with the impact Eastman measured, along with recommendations for supply chain leaders whose planning still relies on handoffs. Meet OMP and explore planning transforma
Innodata to Report Third Quarter 2026 Results15.10.2026 14:05:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / October 15, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Third Quarter 2026 results after the market closes on Thursday, November 5, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are:(+1) 833 296 5777 North America, Toll Free(+44) 808 196 8935 United Kingdom(+1) 206 407 3228 InternationalParticipant Access Code 730 768 717 For Replay: (+1) 833 309 1852 North America-Toll Free(+44) 800 007 4044 United Kingdom(+1) 929 828 5978 InternationalAccess Code 730 768 717 Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only m
Karbon-X (OTCQB:KARX) Secures €1.88 Million (US$2.18 Million) in Net Trading Margin Through New European Low-Carbon Fuel Contracts15.10.2026 13:45:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / October 15, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a global carbon and environmental markets company, today announced that it has established new commercial capabilities and contracted activity across European low-carbon fuels and environmental markets during the first quarter of fiscal 2027. During the first quarter, Karbon‑X secured European low-carbon fuel contracts representing approximately €1.88 million (US$2.18 million) in net trading margin based on the agreed transaction economics. The Company has also secured additional contracted activity extending beyond fiscal 2027, supporting the continued development of its European business. Europe's decarbonization agenda is increasingly moving from broad policy objectives into sector-specific regulatory frameworks. The European Union's Renewable Energy Directive, together with related sector-specific regulations, is accelerating demand for renewable and low-carbon energy and s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom